Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim

Table 1 Combination Index (CI) values at ED ₅₀ and ED ₇₅ in various cancer cell lines

Cell line	Origin	Drug ratio	CI at ED₅₀	CI at ED₇₅
		DOX : Gami
HeLa	cervix	1 : 5	0.33 ± 0.03	0.41 ± 0.03
22Rv1	prostate	1 : 10	0.81 ± 0.18	0.53 ± 0.09
A172	brain	1 : 10	0.45 ± 0.28	0.76 ± 0.27
ACHN	kidney	1 : 2	0.34 ± 0.11	0.20 ± 0.07
SK-Hep1	liver	1 : 5	0.31 ± 0.05	0.29 ± 0.03
NCI-H460	lung	1 : 5	0.32 ± 0.19	0.45 ± 0.29
SK-OV3	ovary	1 : 1	0.58 ± 0.13	0.95 ± 0.28
MDA-MB-231	breast	5 : 1	0.73 ± 0.27	0.46 ± 0.24

NOTE: Cancer cells were treated with various concentrations of drugs at a fixed ratio as indicated. CI values at 50% (ED₅₀) and 75% effective doses (ED₇₅) were calculated from isobologram analysis. Data are the mean ± 1.96 s.d. (95% confidence interval) of two independent experiments performed in triplicate.

ISSN: 1471-2407